LAUSR

We thank our colleagues Holm€ang and Hedelin for their interest in our work and the first national publication reporting lead times and management of bladder cancer in Sweden since the introduction of standardized care pathways in 2015 [1,2]. We appreciate that they have no scientific concerns on the interpretation of the reported data including all bladder cancer patients in the Swedish National Register of Urinary Bladder Cancer (SNRUBC) 2010–2019 representing more than 97% of all patients with bladder cancer in the Swedish Cancer Register. To moderate their somewhat drastic conclusion to abandon standardized care pathways for macroscopic haematuria, some corrections of some of their statements are needed before discussing their proposal further.